MYX Share Price Performance
AU$0
-4.50 (-100.00%)
Price AU$0
Fair ValueAU$4.62
Share Pricen/a
Mayne Pharma Group Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
MYX Community Narratives
AN
Fair Value
·Fair Value AU$4.62 35.0% undervalued intrinsic discount
Women’s Health Trends And Dermatology Platform Will Reshape Long-Term Earnings Profile
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value AU$5.4 44.4% undervalued intrinsic discount
Women’s Health Expansion And Manufacturing Upgrade Will Support Stronger Long-Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value AU$3.83 21.7% undervalued intrinsic discount
Rising Women's Health Costs And Flat Revenue Will Eventually Reveal Underappreciated Earnings Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Mayne Pharma Group
44.4% undervalued intrinsic discount
Women’s Health Expansion And Manufacturing Upgrade Will Support Stronger Long-Term Earnings Potential
View narrativeAN
Published 17 Jul
Mayne Pharma Group
35.0% undervalued intrinsic discount
Women’s Health Trends And Dermatology Platform Will Reshape Long-Term Earnings Profile
View narrativeAN
Updated 2 Jul
Mayne Pharma Group
21.7% undervalued intrinsic discount
Rising Women's Health Costs And Flat Revenue Will Eventually Reveal Underappreciated Earnings Potential
View narrativeAN
Published 2 Jul
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Women’s Health Expansion And Manufacturing Upgrade Will Support Stronger Long-Term Earnings Potential
Fair Value: AU$5.4 44.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Women's Health Costs And Flat Revenue Will Eventually Reveal Underappreciated Earnings Potential
Fair Value: AU$3.83 21.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
None
Fair Value: AU$4.62 35.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Mayne Pharma Group Limited Key Details
About MYX
- Founded
- 2005
- Employees
- 363
- CEO
- WebsiteView website
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
